$Novo-Nordisk A/S(NVO)$ Bought more nvo to dca.
Novo's financial report:
Revenue: $11.87 billion, marking an 18% year-over-year increase, slightly surpassing analyst expectations. 
• Earnings per Share (EPS): $0.99, exceeding forecasts.
• Operating Profit: 20% increase year-over-year to DKr38.8 billion. 
Product Performance:
• Ozempic (Type 2 Diabetes): Generated $4.97 billion in sales, outperforming estimates. 
• Wegovy (Obesity): Sales reached $2.64 billion, a 90% year-over-year increase but a 13% decline from the previous quarter, falling short of the projected $2.8 billion
Nvo is significantly undervalued
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments
Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links: